MARKET EYE-Glenmark gains on USFDA nod for diarrhoea drug

Tue Jan 1, 2013 1:39pm IST

Related Topics

Stocks

   

* Shares in Glenmark Pharmaceuticals gain 2.5 percent
after U.S. health regulators approved Salix Pharmaceuticals
Ltd's drug to treat diarrhoea in HIV/AIDS patients on
qantiretroviral therapy, a combination of medicines used to
treat HIV infection. 
* Glenmark will be the active pharmaceutical ingredients
supplier for the drug to Salix in regulated markets.
* An international arbitrator ruled in August 2012 that Glenmark
Pharmaceuticals has the right to sell its HIV-associated
diarrhoea drug Crofelemer in 140 countries. 
* Edelweiss in a report says, "The overall potential market for
Crofelemer is anticipated at $300 million-$500 million and peak
potential revenue for Glenmark, from API supply, could be $15
million-$20 million per annum."

 (abhishek.vishnoi@thomsonreuters.com /;
abhishek.vishnoi.reuters.com@reuters.net)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

India Economy

REUTERS SHOWCASE

Reliance Projects

Reliance Projects

Exclusive: Reliance plans $13 billion projects including new refinery.  Full Article 

Pharma Sector

Pharma Sector

In race for bigger margins, drug makers willing to lose the India "advantage".  Full Article 

Low Stocks

Low Stocks

Indian power station coal stocks lowest since 2012 blackouts.  Full Article 

Markets This Month

Markets This Month

Tata Motors, M&M top Sensex gainers  Full Article 

Google Drones

Google Drones

Google is testing unmanned drones to deliver anything from dog food to medicine.  Video 

#RiceBucketChallenge

#RiceBucketChallenge

In India, rice replaces ice in bucket challenge.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage